homoscedasticity assumption in RSABE method [RSABE / ABEL]

posted by WinnieH – Sweden, 2023-08-18 10:57 (114 d 23:49 ago) – Posting: # 23697
Views: 1,067

Dear all,

I had a question related to the homoscedasticity assumption in the RSABE method when I read the tutorial of PowerTOST.

If the RSABE method is performed on the highly variable drug with the 4-way crossover design (not the NTI drug), is the homoscedasticity assumption always holden? And I think if a 3-way crossover design is used, there is no way to assume the homoscedasticity since the test drug is administered once and we can not calculate the WSV of the test drug.

A further question is, when do we assume the reference and test product have equal variances, i.e. CVwT ≡ CVwR? And why?

Thank you so much and looking forward to your reply!


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,823 posts in 4,786 threads, 1,633 registered users;
41 visitors (0 registered, 41 guests [including 6 identified bots]).
Forum time: 09:46 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz